TRANSFORM
2018
Transplant Efficacy and Safety Outcomes with an Everolimus-based Regimen
In 2,037 de-novo kidney-transplant recipients, everolimus with reduced calcineurin inhibitor was non-inferior for rejection, graft loss or death compared with mycophenolate with standard calcineurin inhibitor.
Result
- Absolute difference
- 3.1 points
difference3.295% CI -1.3 to 7.6
The absolute difference is derived from the event rates.
Also reported: Non-inferior. Discontinuation for AEs 23.0% vs 11.9%.
- Subtopic
- mTOR inhibitors
- Design
- Open-label RCT
- Relevance
- Supporting: context rather than must-know.
- Source
- Pascual J, et al. J Am Soc Nephrol. 2018;29(7):1979-1991.doi 10.1681/ASN.2018010009
Discussion & critique
The largest de-novo mTOR-inhibitor trial; tolerability limits uptake.